Accès gratuit
Med Sci (Paris)
Volume 17, Numéro 11, Novembre 2001
Page(s) 1189 - 1191
Section Nouvelles
Publié en ligne 15 novembre 2001
  1. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000; 103 : 211–25.
  2. Bonaventure J, Rousseau F, Legeai-Mallet L, et al. Récepteurs des facteurs de croissance fibroblastique (FGFR) et anomalies héréditaires de l’ossification enchondrale et membranaire. Med Sci 1996; 12 : 44–9.
  3. Webster MK, Donoghue DJ. FGFR activation in skeletal disorders: too much of a good thing. Trends Genet 1997; 13 : 178–82.
  4. Chesi M, Nardini E, Brents LA, et al. Frequent translocation t(4 ;14)(p16.3 ;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 1997; 16 : 260–4
  5. Richelda R, Ronchetti D, Baldini L, et al. A novel chromosomal translocation t(4 ; 14)(p16.3 ; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. Blood 1997; 90 : 4062–70.
  6. Fracchiolla NS, Luminari S, Baldini L, Lombardi L, Maiolo AT, Neri A. FGFR3 gene mutations associated with human skeletal disorders occur rarely in multiple myeloma. Blood 1998; 92 : 2987–9.
  7. Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM, Bergsagel PL. The t(4 ;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 1998; 92 : 3025–34.
  8. Stec I, Wright TJ, van Ommen GJ, et al. WHSC1, a 90 kb SET domain-containing gene, expressed in early development and homologous to a Drosophila dysmorphy gene maps in the Wolf-Hirschhorn syndrome critical region and is fused to IgH in t(4 ;14) multiple myeloma. Hum Mol Genet 1998; 7 : 1071–82.
  9. Cappellen D, De Oliveira C, Ricol D, et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999; 23 : 18–20.
  10. Billerey C, Chopin D, Aubriot-Lorton MH, et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 2001; 158 : 1955–9.
  11. Karoui M, Hofmann-Radvanyi H, Zimmermann U, et al. No evidence of somatic FGFR3 mutation in various types of carcinoma. Oncogene 2001; 20 : 5059–61.
  12. Lee R, Droller MJ. The natural history of bladder cancer. Implications for therapy. Urol Clin North Am 2000; 27 : 1–13, vii.
  13. Spruck CH, Ohneseit PF, Gonzalez-Zulueta M, et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994; 54 : 784–8.
  14. van Rhijn BW, Lurkin I, Radvanyi F, Kirkels WJ, van der Kwast TH, Zwarthoff EC. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 2001; 61 : 1265–8.
  15. Sybley K, Cuthbert-Heavens D, Knowles MA. Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma. Oncogene 2001; 20 : 686–91.
  16. Ronchetti D, Greco A, Compasso S, et al. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4 ;14) : comparative analysis of Y373C, K650E and the novel G384D mutations. Oncogene 2001; 20 : 3553–62.